Rene Russo - Jan 1, 2025 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Kevin Brennan, Attorney-in-Fact
Stock symbol
XLO
Transactions as of
Jan 1, 2025
Transactions value $
$0
Form type
4
Date filed
1/3/2025, 04:15 PM
Previous filing
May 3, 2024
Next filing
Apr 16, 2025
SEC
View on sec.gov
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XLO Common Stock Options Exercise +44.3K +22.06% 245K Jan 1, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Restricted Stock Units Options Exercise $0 -44.3K -25% $0.00 133K Jan 1, 2025 Common Stock 44.3K Direct F1, F2
transaction XLO Stock Option (right to buy) Award $0 +638K $0.00 638K Jan 1, 2025 Common Stock 638K $0.96 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs) convert to stock on a one-for-one basis
F2 These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028.
F3 The option was granted on January 1, 2025 and will vest in 48 equal monthly installments beginning on February 1, 2025 and continuing through January 1, 2029.